ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GENE Genetic Technologies Ltd

2.33
0.0754 (3.34%)
Last Updated: 16:51:21
Delayed by 15 minutes
Name Symbol Market Type
Genetic Technologies Ltd NASDAQ:GENE NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.0754 3.34% 2.33 2.32 2.35 2.49 2.31 2.49 17,939 16:51:21

Genetic Technologies Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

13/05/2021 2:01pm

GlobeNewswire Inc.


Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Genetic Technologies Charts.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, today announced an interview with Simon Morriss, CEO, will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on Saturday, May 15th, at 7 p.m. local time in 73M homes across the United States.

In the exclusive interview, Mr. Morriss discusses the Company’s upcoming milestones, updates on the company’s lead risk assessment products, GeneType for Breast Cancer, for non-hereditary breast cancer and GeneType for Colorectal Cancer, as well as their Covid19 Risk Assessment test. Mr. Morriss also discusses the company’s developing pipeline of risk assessment products and commercialization plans.

To view the interview segment, please visit: https://youtu.be/-o-2YWJ7FyU

“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com

Investor Relations (AUS)Investor Relations and Media (US)
Stephanie OttensDave Gentry
Market Eye1 800 RED CHIP (733 2447)
M: +61 434 405 400Cell: 407 491 4498
E: stephanie.ottens@marketeye.com.auE: dave@redchip.com

1 Year Genetic Technologies Chart

1 Year Genetic Technologies Chart

1 Month Genetic Technologies Chart

1 Month Genetic Technologies Chart

Your Recent History

Delayed Upgrade Clock